Rottendorf Pharmaceuticals continues growth with multiple new deals with top-five pharmas

Company also received five separate 2015 contract manufacturing-oriented Leadership Awards recently presented by Life Science Connect

Jeffrey Bouley
CHICAGO—Rottendorf Pharmaceuticals, a contract development and manufacturing organization (CDMO) currently producing 600 products for more than 200 clients worldwide, announced in March that is had signed in the last quarter three formulation development projects and two commercial transfer projects with multiple top-five pharmaceutical and biopharmaceutical  companies. The five new projects capped what the company—the U.S.-based subsidiary of Rottendorf Pharma GmbH—calls “a strong year of growth” in which it has more than doubled its share of corporate revenue since 2011.
 
The new projects signed in the last quarter reflect the industry’s positive response to the company’s business model and its commitment to what it has dubbed (and trademarked) Total Process Ownership (TPO), according to Rottendorf Pharmaceuticals CEO Gordon Haines.
 
“TPO relies on open communication and exchange of ideas with our pharma partners and draws on 85 years of formulation development and manufacturing experience to recommend process optimizations to ultimately produce a better end product,” he explained in a news release about the company’s progress.
 
As the company explains, under TPO Rottendorf assumes a high degree of process responsibility and ownership. Reported benefits to clients of TPO include reduced management oversight, lower costs due to reduced complexity, supply chain improvements and products of the highest quality at the lowest total cost.
 
Haines noted that a significant number of new clients come to the company as a result of word-of-mouth referrals from satisfied clients who have benefited from the proactive approach Rottendorf takes to process improvement. Clients also appreciate the CDMO’s unique corporate structure.
 
“We are owned by a charitable foundation, which allows us to focus more on long-term success of our business and the goals of our customers, rather than needing to satisfy shareholders on a quarter-by-quarter basis,” Haines added.
 
Adding additional feathers to its cap, the company also noted that five separate 2015 CMO Leadership Awards recently were presented to Rottendorf by Life Science Connect and thus “reflect this laser-sharp focus on long-term customer success.”
 
The awards reflect survey results of more than 65,000 questionnaires sent to a broad swath of the industry, including both pharma and biotech companies. Rottendorf won two awards for quality (from both big pharma and emerging biotech firms), one for productivity (from mid-sized and specialty pharma), one for innovation (from emerging pharma) and one for regulatory (from emerging biotech firms).
 
“These awards show that our customers appreciate the proactive approach we take to working with them and serve as further proof that our unique approach resonates with the market,” concluded Haines.

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022